CriticalDirect thrombin inhibitor×Direct oral anticoagulants (factor Xa inhibitors)
Updated · Methodology
Mechanism
Edoxaban directly and reversibly inhibits clotting factor Xa, and dabigatran directly and reversibly inhibits thrombin. Both drugs interfere with thrombus formation (edoxaban and dabigatran summaries of product characteristics, SmPCs, European Medicines Agency, EMA). Both SmPCs contraindicate use with any other anticoagulant, and the edoxaban SmPC names dabigatran (EMA). Healthy volunteers took dabigatran for three days and switched to edoxaban on day 4. Their activated partial thromboplastin time (aPTT) was higher than with edoxaban alone because of the residual effect of dabigatran. Bleeding time, however, was not prolonged (edoxaban SmPC, EMA). This is why the first edoxaban dose after a switch can be given at the time of the next scheduled dose of the previous drug (EMA).
Symptoms
Edoxaban increases the risk of bleeding, which can be severe or even fatal and can occur at any site (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia. Bleeding can present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause (EMA). If haemoglobin or blood pressure falls without explanation, look for a bleeding site. Standard coagulation tests are not suitable for monitoring the effect of edoxaban (EMA). In the RE-LY study, other oral or parenteral anticoagulants raised major bleeding rates about 2.5-fold with both dabigatran and warfarin. This happened mainly when patients switched from one anticoagulant to another (dabigatran SmPC, EMA).
Management
Edoxaban is contraindicated with any other anticoagulant, except when switching from one oral anticoagulant to another. The edoxaban summary of product characteristics (SmPC) names dabigatran in this contraindication (edoxaban SmPC, European Medicines Agency, EMA). The dabigatran SmPC likewise contraindicates any other anticoagulant except in specific circumstances, including a switch of anticoagulant therapy (dabigatran SmPC, EMA). When switching from dabigatran to edoxaban, stop dabigatran and start edoxaban at the time of the next scheduled dabigatran dose (edoxaban SmPC, EMA). When switching from edoxaban to dabigatran, stop edoxaban and start dabigatran at the time of the next scheduled edoxaban dose (EMA). The US label does not recommend long-term use of edoxaban with other anticoagulants (edoxaban label, US Food and Drug Administration, FDA). Promptly evaluate any signs of blood loss (FDA). If severe bleeding occurs, stop edoxaban. There is no specific antidote (EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: SAVAYSA (edoxaban) tablets, prescribing information (2023)– FDA, SAVAYSA (edoxaban tosylate) prescribing information, Daiichi Sankyo, NDA 206316, revised 10/2023 (DailyMed)
- EMA: Ficha técnica: Edoxabán, Lixiana 60 mg (EU/1/15/993), sección 4.3 (2025)– EMA SmPC vía AEMPS CIMA, Lixiana 60 mg comprimidos recubiertos con película (Daiichi Sankyo Europe), nº registro 115993018 (EU/1/15/993), información de producto EMA actualizada 27/08/2025, consultada 30.10.2026, secciones 4.2, 4.3, 4.4, 4.5, 4.8, 4.9 y 5.1
- EMA: Ficha técnica: Dabigatrán etexilato, Pradaxa 150 mg (EU/1/08/442), sección 4.3 (2026)– EMA SmPC vía AEMPS CIMA, Pradaxa 150 mg cápsulas duras (Boehringer Ingelheim International), nº registro 08442011 (EU/1/08/442), información de producto EMA actualizada 28/10/2026 (página EPAR), texto consultado en CIMA 30.10.2026, secciones 4.2, 4.3, 4.5 y 5.1